Last updated on November 2018

A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma

Brief description of study

The purpose of this study is to determine whether the combination of nivolumab and ipilimumab is safe and effective for delaying or preventing recurrence of cancer in patients who have experienced the partial or entire removal of a kidney

Clinical Study Identifier: NCT03138512

Contact Investigators or Research Sites near you

Start Over

Site 0140

Local Institution
Nanchang, China
  Connect »